Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy
The aim of review. To characterize advantage of application of a leukocytic interferon a (IFN-a) for prophylaxis of cytopenia at antiviral therapy of chronic hepatitis C (CHC).Original positions. Hematological undesirable effects of antiviral agents represent the most serious complication of etiolog...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2009-06-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1632 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341866040885248 |
|---|---|
| author | A. O. Buyeverov |
| author_facet | A. O. Buyeverov |
| author_sort | A. O. Buyeverov |
| collection | DOAJ |
| description | The aim of review. To characterize advantage of application of a leukocytic interferon a (IFN-a) for prophylaxis of cytopenia at antiviral therapy of chronic hepatitis C (CHC).Original positions. Hematological undesirable effects of antiviral agents represent the most serious complication of etiological treatment of CHC. Thus development of neutropenia and thrombocytopenia is related first of all to application of IFN-a. The basic approach to cope with hematological complications includes prescription of hemopoietic factors at already developed cytopenia. Possible delay of correcting preparation action and increase of the total treatment cost is disadvantage of this approach. Choice of the most safe medicine that is justified, first of all, at patients with initially present cytopenias or having those at previous courses of antiviral therapy may be an alternative. It is possible to offer leukocytic IFN-a «Alfaferone» As such a drug, which efficacy, at least in CHC patients with non-1-st genotype, is not lower, and even is higher, than that of recombinant analogues. At prescription of leukocytic IFN-a necessity in hemopoietic factors maintenance therapy develops rather rarely, in which case significantly lower doses and duration of treatment is required.Conclusion. Application of leukocytic IFN-a within antiviral therapy of CHC is characterized by high efficacy and safety that allows to recommend it as a drug of choice at «difficult» categories of patients. |
| format | Article |
| id | doaj-art-e620769b41194e51b69adf461336bbbb |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2009-06-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-e620769b41194e51b69adf461336bbbb2025-08-20T03:43:33ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732009-06-0119376811130Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapyA. O. Buyeverov0Московская медицинская академия им. И.М. СеченоваThe aim of review. To characterize advantage of application of a leukocytic interferon a (IFN-a) for prophylaxis of cytopenia at antiviral therapy of chronic hepatitis C (CHC).Original positions. Hematological undesirable effects of antiviral agents represent the most serious complication of etiological treatment of CHC. Thus development of neutropenia and thrombocytopenia is related first of all to application of IFN-a. The basic approach to cope with hematological complications includes prescription of hemopoietic factors at already developed cytopenia. Possible delay of correcting preparation action and increase of the total treatment cost is disadvantage of this approach. Choice of the most safe medicine that is justified, first of all, at patients with initially present cytopenias or having those at previous courses of antiviral therapy may be an alternative. It is possible to offer leukocytic IFN-a «Alfaferone» As such a drug, which efficacy, at least in CHC patients with non-1-st genotype, is not lower, and even is higher, than that of recombinant analogues. At prescription of leukocytic IFN-a necessity in hemopoietic factors maintenance therapy develops rather rarely, in which case significantly lower doses and duration of treatment is required.Conclusion. Application of leukocytic IFN-a within antiviral therapy of CHC is characterized by high efficacy and safety that allows to recommend it as a drug of choice at «difficult» categories of patients.https://www.gastro-j.ru/jour/article/view/1632chronic hepatitis ctreatmentleukocytic interferon ahematological complications |
| spellingShingle | A. O. Buyeverov Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy Российский журнал гастроэнтерологии, гепатологии, колопроктологии chronic hepatitis c treatment leukocytic interferon a hematological complications |
| title | Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy |
| title_full | Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy |
| title_fullStr | Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy |
| title_full_unstemmed | Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy |
| title_short | Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy |
| title_sort | treatment and prophylaxis of hematological side effects of chronic hepatitis c antiviral therapy |
| topic | chronic hepatitis c treatment leukocytic interferon a hematological complications |
| url | https://www.gastro-j.ru/jour/article/view/1632 |
| work_keys_str_mv | AT aobuyeverov treatmentandprophylaxisofhematologicalsideeffectsofchronichepatitiscantiviraltherapy |